|
: Reports Critical NEWS ALERTS -- City Telecom Ltd. (NASDAQ: CTEL), Atmel Corporation (NASDAQ: ATML), NetApp (NASDAQ: NTAP), Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA): Sign-Up for our FREE Stock Alerts TODAY!
Sep 10, 2010 (M2 PRESSWIRE via COMTEX) --
www.OTCtipReporter.com Reports Critical NEWS ALERTS aEUR" City Telecom Ltd. (NASDAQ: CTEL), Atmel Corporation (NASDAQ: ATML), NetApp (NASDAQ: NTAP), Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA)
Sign-Up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK aEURoehttp://www.OTCtipReporter.com/aEUR www.OTCtipReporter.com
_____________________________________________________________________________
Visit: www.OTCtipReporter.com
PHENOMENAL Singapore Experience for our Front Line Talents
HONG KONG, Sept. 8, 2010 aEUR" At City Telecom (H.K.) Limited (aEURoeCity TelecomaEUR) (Nasdaq:CTEL), we think differently. Whilst many companies in the service industry tend to outsource their customer contact points due to the labor intensive nature of this business, we look to keep the fair majority of our customer contact points in-house, hence our pool of over 3,000 full time Talents spread between Hong Kong and Guangzhou.
Whilst our Talent development policies are extremely tough aEUR" for example, we terminate the bottom 5% of our salary base annually aEUR" this allows us to concentrate on nurturing and rewarding our top 95% of performers. Given that we set very aggressive performance targets a year ago and we have since achieved them, this PHENOMENAL Singapore Experience is a reward trip for our top 350 non-management grade Talents, who have shown exceptional customer service, be it external or internal.
Approximately half of the total participants were from our Guangzhou call centre, and for many, this was their first international trip. The full trip album can be downloaded at http://reg.hkbn.net/ctigroup_admin/files_upload/201009_Trip_Summary_Singapore.pdf
Some quotes from the trip participants:
Ms Mak Chiu Lai, Office Cleaner, Hong Kong, aEURoeVery excited aEUR" itaEUR(TM)s the first time for me to go overseasaEUR
Mr Chan, Kwok Ching, Senior Sales Executive, Hong Kong, aEURoeaEUR~CorporateaEUR(TM) feel aEUR" not stand-alone individual!aEUR
Mr Zhang Xiao Long, Telesales Executive, Guangzhou, aEURoeA great opportunity to meet HK teammates, and facilitate the networking thereafteraEUR
NiQ Lai
CFO & Head of Talent Engagement
About City Telecom/Hong Kong Broadband Network Limited
Established in 1992, City Telecom (H.K.) Limited (Nasdaq:CTEL) provides integrated telecommunications services in Hong Kong via its own self-built fibre network. City TelecomaEUR(TM)s wholly-owned subsidiary, Hong Kong Broadband Network Limited (HKBN), is the fastest growing broadband service provider in Hong Kong. HKBN offers a diversified portfolio of innovative products that service over 1,027,000 subscriptions for broadband, local telephony and IP-TV. The Company has built a solid market position with top-of-the-line applications and practices enabling it substantial growth. The company takes great pride in developing its over 3,000 Talent force into a competitive advantage. Additional information on City Telecom can be found at www.ctigroup.com.hk.
_____________________________________________________________________________
Visit: www.OTCtipReporter.com
Atmel QTouch Studio 4.3 Software Tool Eases Touch Designs
QTouch Studio 4.3 addresses every phase of a touch design and includes the industryaEUR(TM)s first Touch Validation Wizard, accelerating time-to-market with intelligent touch interface design
SAN JOSE, Calif., Sept. 8, 2010 aEUR" Atmel Corporation (Nasdaq: ATML), a leader in microcontroller and touch solutions, today launched the Atmel QTouch Studio 4.3 - the industryaEUR(TM)s first touch design software tool to support the complete touch design flow. Another first is the Touch Validation Wizard, a feature in the Atmel QTouch Studio 4.3 to help assess design quality by reporting capacitance, noise and reference levels, as well as notifying the user of design marginalities. The software tool is so easy to use that design engineers do not need an expert level of understanding of touch technologies to quickly and effectively integrate touch functionality into their applications.
With Atmel QTouch Studio 4.3, designers can quickly enhance their designs with touch functionality while bringing their products to market faster, thereby reducing the overall engineering workload and accelerating their time to revenue. This software tool supports real-time tuning of the touch sensors, permanent storage of the tuned configuration data into the flash memory, design validation, and debug of the touch interface. Engineers can now easily expand their sensor and manufacturing supply chain by qualifying their systems for multiple material suppliers or contract manufacturers, while testing the performance of the touch interface during development or in production.
The Atmel QTouch Studio 4.3 supports Atmel AVR 8- and 32-bit and ARM microcontroller devices. This software tool can also be used with the Atmel touch evaluation and development kits, including the QT600.
aEURoeAtmel is committed to making it easy for design engineers to implement touch in their designs,aEUR said Steve Berry, marketing director for touch technologies at Atmel Corporation. aEURoeQTouch Studio 4.3 enables engineers in any market to integrate touch functionality into their system designs. The Touch Validation Wizard that weaEUR(TM)ve added in this release is the first of its kind to provide quantitative and qualitative data back to the user, informing the user if any of the touch design rules have been violated.aEUR
The Atmel QTouch Studio 4.3 is a free software application that provides real-time tuning, validation, debug, and visualization of touch interfaces. This software is supported by Microsoft Windows XP, Vista and Windows 7.
Availability and Pricing
Atmel QTouch Studio 4.3 is available now, free of charge, and can be downloaded from our touch software product page at http://www.atmel.com/dyn/products/tools_card.asp?tool_id=4445.
Information
More information about the Atmel QTouch Suite is available at http://www.atmel.com/products/touchsoftware/qtouchsuite.asp?family_id=702.
For further information on Atmel Touch Solutions, visit: http://www.atmel.com/touch.
About Atmel
Atmel Corporation (Nasdaq: ATML) is a worldwide leader in the design and manufacture of microcontrollers, capacitive touch solutions, advanced logic, mixed-signal, nonvolatile memory and radio frequency (RF) components. Leveraging one of the industryaEUR(TM)s broadest intellectual property (IP) technology portfolios, Atmel is able to provide the electronics industry with complete system solutions focused on industrial, consumer, security, communications, computing and automotive markets.
2010 Atmel Corporation. All Rights Reserved. Atmel, Atmel logo and combinations thereof, QTouch, QTouch Studio, AVR, and others are trademarks or registered trademarks of Atmel Corporation or its subsidiaries. ARM is a registered trademark of ARM Ltd. or its subsidiaries. Other terms and product names may be trademarks of others.
_____________________________________________________________________________
Visit: www.OTCtipReporter.com
NetApp Founder Dave Hitz to Drive Discussion Around Storage Efficiency at Oracle OpenWorld 2010
SUNNYVALE, CA aEUR" 09/09/10 aEUR" NetApp (NASDAQ: NTAP) Founder and Executive Vice President Dave Hitz will present an Executive Solutions session focusing on storage efficiency at Oracle OpenWorld 2010. Other NetApp executives, experts, and customers will also present at the show. NetApp is a Premier sponsor of Oracle OpenWorld 2010, which takes place September 19-23, 2010, at Moscone Center in San Francisco, California.
During the show, NetApp will demonstrate how NetApp with Oracle can not only be a storage platform for customers, but also a storage efficiency solution. The NetApp booth (1501) will also feature NetApp data management solutions for Oracle that lower costs and improve efficiency.
Following is a list of the various sessions NetApp will present during Oracle OpenWorld:
Session: Executive Solutions Session: aEURoeAddition by Subtraction: The New
Equation for Your Data CenteraEUR
Speakers: Dave Hitz, founder and executive vice president, NetApp
Rich Bernat, senior DBA/Basis administrator, Chevron
Date: Monday, September 20
Time: 12:30-1:30 p.m., PT
Session: aEURoeNetApp SOA Journey: Adoption of Oracle Application Integration
ArchitectureaEUR
Speakers: Alok Arora, director, Enterprise Architecture, NetApp
Kailash Randad, architect, NetApp
Raman Mehta, Solution director, Oracle
Date: Tuesday, September 21
Time: 5:00-6:00 p.m., PT
Session: aEURoeModernize Your Data Center with Oracle Virtualization and
NetAppaEUR
Speakers: Rich Clifton, senior vice president and general manager,
Technology Enablement & Solutions Organization, NetApp
Wim Coekaerts, senior vice president, Linux and Virtualization,
Oracle
Padmanabhan Sadagopan, Solutions architect, NetApp
Stephen Bartholomew, Enterprise architect, Verizon
Date: Wednesday, September 22
Time: 10:00-11:00 a.m., PT
Session: aEURoeSprint Case Study: Creating the WorldaEUR(TM)s Largest Call-Tracking
Data WarehouseaEUR
Speakers: Steve Daniel, director, Database Platforms and Performance
Technology, NetApp
Richard Ewald, Sprint
Date: Wednesday, September 22
Time: 1:00-2:00 p.m., PT
Session: aEURoeIntroduction and Update: Oracle Hyperion Data Relationship
ManagementaEUR
Speakers: Luda Shuster, NetApp
Rahul Kamath, director, Product Strategy, Oracle
Date: Wednesday, September 22
Time: 4:45-5:45 p.m., PT
Session: aEURoeExtreme Throughput with Oracle Real Application Clusters, 10
GbE, and NetAppaEUR
Speakers: Brandon Hoang, senior Oracle Alliance architect, NetApp
Ruiping Sun, principal architect, Yahoo, Inc.
Date: Thursday, September 23
Time: 1:30-2:30 p.m., PT
Session: aEURoeCERN Achieves Database Scalability and Performance with Oracle
and NetAppaEUR
Speakers: Steve Daniel, director, Database Platforms and Performance
Technology, NetApp
Eroc Grancher, DBA team leader, CERN
Date: Thursday, September 23
Time: 3:00-4:00 p.m., PT
NetApp Booth: 1501
Registration: For complete information or to register for the event, please visit: www.oracle.com/us/openworld/
For more information about NetApp at Oracle OpenWorld 2010, please visit: http://communities.netapp.com/community/events/openworld.
For up-to-the-minute information about NetApp at Oracle OpenWorld 2010, follow NetApp on twitter: http://twitter.com/netapp.
Discuss this news in the NetApp Community, where you can exchange thoughts and ideas on a variety of topics with our community members. Collaborate with our company, engage in conversation with NetApp leaders and employees, and participate in our passion to go further, faster. Join now at http://communities.netapp.com.
About NetApp
NetApp creates innovative storage and data management solutions that deliver outstanding cost efficiency and accelerate business breakthroughs. Discover our passion for helping companies around the world go further, faster at www.netapp.com.
NetApp, the NetApp logo, and Go further, faster are trademarks or registered trademarks of NetApp, Inc. in the United States and/or other countries. Oracle is a registered trademark of Oracle Corporation. All other brands or products are trademarks or registered trademarks of their respective holders and should be treated as such.
_____________________________________________________________________________
Visit: www.OTCtipReporter.com
QVAR Versus Fluticasone in a Real-World Study Highlights the Importance of Inhaled Corticosteroid (ICS) Choice in Achieving Asthma Control
Study reveals that patients treated with QVAR had a similar or better chance of achieving asthma control at lower prescribed doses than with fluticasone
HORSHAM, Pa., Sept. 8, 2010 aEUR" Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced the publication of results from a real-life observational study of the General Practice Research Database (GPRD), which revealed that asthma patients treated with QVAR (beclomethasone dipropionate HFA), either as initial therapy or with an increase (step up) in dose, had a similar or better chance of achieving asthma control as patients who were treated with fluticasone propionate (Flovent). Asthma control was achieved in the QVAR population at lower doses of drug versus those in the Flovent population. These results were published in the September issue of the Journal of Allergy and Clinical Immunology (JACI) and are available at www.jacionline.org/inpress.
aEURoeThe results of TevaaEUR(TM)s most recent study using the GPRD database reinforce the effectiveness of ICS monotherapy in achieving asthma control for most patients who either initiate ICS therapy or who are already on an ICS and need a step up in dose,aEUR said Paul Dorinsky, MD, Vice President, Teva Global Respiratory Research and Development. aEURoeIn fact, over 85% of the study patients achieved the primary measure of asthma control as defined by the study. The GPRD findings are timely given the recent FDA guidance advocating limited use of products containing long-acting beta-agonists (LABAs), including LABA-plus-ICS combination products, while recommending more aggressive treatment with monotherapy ICS agents. We are also encouraged that patients in the initiation population of the study treated with QVAR achieved better asthma control at lower prescribed doses of drug, as a key goal of asthma management is to use the lowest dose needed to achieve overall asthma control and prevent exacerbations. In the step up population, patients receiving QVAR had a similar chance of achieving asthma control at lower prescribed doses than with Flovent. In both populations, the rate of exacerbations was not significantly different between the QVAR and Flovent patient groups.aEUR
Historically, the choice of ICS has been driven by a number of criteria, including cost and convenience. Less emphasis has been placed on therapeutic index, as no randomized controlled trials have consistently demonstrated clinically meaningful differences in outcomes among available ICS options. The present study using the GPRD database is a rigorously conducted, real-world observational study that compared the clinical effectiveness of QVAR and Flovent, two ICS agents that have different formulations and product attributes. This highlights the importance and potential value/relevance of real-world, retrospective studies in evaluating therapeutic options within a class of drugs.
aEURoeRetrospective studies like the GPRD study provide real-life evidence that indicates there may be clinically meaningful differences in asthma outcomes, depending on which ICS agent is used,aEUR said David Price, Primary Care Respiratory Society professor of primary care respiratory medicine, University of Aberdeen Center of Academic Care and lead investigator of the study. aEURoeQVARaEUR(TM)s smaller particle size combined with its delivery system allows it to be distributed throughout the entire lung, where it reaches and treats the inflammation in the large and small airways associated with asthma. The benefits demonstrated by QVAR in this study may be associated with the productaEUR(TM)s ability to treat both the large and small airways.aEUR
As governments, patients and physicians continue their search for medicines that are efficacious, safe and cost-effective, the GPRD findings have important implications as to how QVAR and Flovent could be implemented in clinical practice moving forward.
About the Study
The objective of this retrospective, observational study was to compare asthma-related outcomes over 1 year as recorded in a primary care database for patients aged 5-60 years receiving a first prescription (initiation population) or dose increase (step-up population) of hydrofluoroalkane HFA-beclomethasone (QVAR) or fluticasone (HFA or CFC formulation) delivered by metered-dose inhaler (MDI). Patients in both the initiation and step-up groups were selected using a matched cohort analysis that matched patients based on baseline disease severity, therapy, and demographic characteristics. Co-primary outcomes were asthma control (a composite measure comprising no unplanned visit or hospitalization for asthma, oral corticosteroids, or antibiotics for lower respiratory infection) and exacerbation rate.
About GPRD
The General Practice Research Database (GPRD) is a large, well-maintained database, administered as a not-for-profit by the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency that contains deidentified longitudinal medical records from approximately 500 primary care practices in the UK. Patient records in the GPRD total 13 million; and active records number 3.6 million, equivalent to 5.5% of the UK population. The demographic characteristics of patients included in the GPRD are considered broadly representative.
The GPRD is the largest and most comprehensive source of data of its kind and is used worldwide for research by the pharmaceutical industry, clinical research organizations, regulators, government departments and leading academic institutions.
About Asthma
Asthma is a chronic (long-term) disease of inflammation of both the large and small airways of the lung, characterized by symptoms of wheezing and coughing. Asthma causes recurring periods of wheezing (a whistling sound when you breathe), chest tightness, shortness of breath and coughing that often occurs at night or early in the morning. Without appropriate treatment, asthma symptoms may become more severe and result in an asthma attack, which can lead to hospitalization and even death.
About QVAR
QVAR is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for systemic corticosteroids.
Important Safety Information
QVAR does not replace fast-acting (rescue) inhalers for sudden symptoms.
If you are switching from an oral corticosteroid to QVAR, follow your doctoraEUR(TM)s instructions to avoid health risks when you stop using oral corticosteroids.
Inhaled corticosteroids may cause a reduction in growth rate. The long-term effect on final adult growth is unknown.
In clinical studies, common side effects included headache and pharyngitis.
Do not stop taking QVAR abruptly without talking to your doctor.
QVAR is a registered trademark of IVAX LLC, a member of the TEVA Group.
For full Prescribing Information, please click here: http://www.qvar.com/Document/PrescribingInformation.pdf.
About Teva
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of TevaaEUR(TM)s sales are in North America and Western Europe.
TevaaEUR(TM)s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managementaEUR(TM)s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Neurontin, Lotrel, Protonix and Yaz, the extent to which any manufacturing or quality control problems damage our reputation for high quality production, the effects of competition on sales of our innovative products, especially Copaxone (including potential generic and oral competition for Copaxone), the impact of continuing consolidation of our distributors and customers, our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of ratiopharm), interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, intense competition in our specialty pharmaceutical businesses, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, dependence on the effectiveness of our patents and other protections for innovative products, our ability to achieve expected results through our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, our potential exposure to product liability claims to the extent not covered by insurance, the termination or expiration of governmental programs or tax benefits, current economic conditions, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in this report and in our other filings with the U.S. Securities and Exchange Commission (aEURoeSECaEUR).
_____________________________________________________________________________
Visit: www.OTCtipReporter.com
About OTCtipReporter.com
www.OTCtipReporter.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.
www.OTCtipReporter.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity. To subscribe to this free service, visit the OTCtipReporter Stock Report home page at http://www.OTCtipReporter.com and Sign up Free For aEURoeDaily Stock AlertsaEUR.
Join us at http://www.OTCtipReporter.com for a complimentary subscription to the most exciting online financial newsletter on the market.
Disclaimer: Verify all claims and do your own due diligence. OTCtipReporter.com profiles are not a solicitation or recommendation to buy, sell or hold securities. OTCtipReporter.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. OTCtipReporter.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), OTCtipReporter.com is owned and operated by OTCtipReporter.com. Neither OTCtipReporter.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this press-release, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since OTCtipReporter.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in OTCtipReporter.com statements and opinions and such statements and opinions cannot be considered independent. OTCtipReporter.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains aEURoeforward looking statementsaEUR within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be aEURoeforward looking statementsaEUR. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. OTCtipReporter.com services are often paid for using free-trading shares. OTCtipReporter.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
Visit us for a full Disclaimer at: http://www.otctipreporter.com/disclaimer.asp
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
[ InfoTech Spotlight's Homepage ]
|
